Silverback Therapeutics: From Niche to Billion-Dollar Opportunity?
Reading Time: 2 minutes
Silverback Therapeutics is a clinically-oriented biotechnology company based in Seattle that specializes in the development of innovative "ImmunoTAC" therapeutics – highly precise antibodies that specifically transport immunomodulatory molecules to tumor- or tissue-specific areas. Since its IPO in December 2020, during which the company raised approximately $126 million, it has continuously expanded its pipeline and currently operates several programs, including antibody-drug candidates against cancer and chronic viral diseases like HBV. With...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
